The role of carfilzomib in relapsed/refractory multiple myeloma
Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and a...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-06-01
|
| Series: | Therapeutic Advances in Hematology |
| Online Access: | https://doi.org/10.1177/20406207211019612 |
| _version_ | 1823969171264765952 |
|---|---|
| author | Andrew J. Yee |
| author_facet | Andrew J. Yee |
| author_sort | Andrew J. Yee |
| collection | DOAJ |
| description | Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and as a partner in diverse three drug combinations such as with lenalidomide or daratumumab. While it has an established place in relapsed disease, clinicians should be aware of its cardiovascular and renal adverse event profile, which is manageable, in order to optimize outcomes. This review will provide a perspective on the current and future role of carfilzomib in relapsed/refractory multiple myeloma. |
| first_indexed | 2024-12-17T18:53:18Z |
| format | Article |
| id | doaj.art-3581cfe2d0a14b92a238766458dbfe95 |
| institution | Directory Open Access Journal |
| issn | 2040-6215 |
| language | English |
| last_indexed | 2024-12-17T18:53:18Z |
| publishDate | 2021-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Hematology |
| spelling | doaj.art-3581cfe2d0a14b92a238766458dbfe952022-12-21T21:36:27ZengSAGE PublishingTherapeutic Advances in Hematology2040-62152021-06-011210.1177/20406207211019612The role of carfilzomib in relapsed/refractory multiple myelomaAndrew J. YeeCarfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and as a partner in diverse three drug combinations such as with lenalidomide or daratumumab. While it has an established place in relapsed disease, clinicians should be aware of its cardiovascular and renal adverse event profile, which is manageable, in order to optimize outcomes. This review will provide a perspective on the current and future role of carfilzomib in relapsed/refractory multiple myeloma.https://doi.org/10.1177/20406207211019612 |
| spellingShingle | Andrew J. Yee The role of carfilzomib in relapsed/refractory multiple myeloma Therapeutic Advances in Hematology |
| title | The role of carfilzomib in relapsed/refractory multiple myeloma |
| title_full | The role of carfilzomib in relapsed/refractory multiple myeloma |
| title_fullStr | The role of carfilzomib in relapsed/refractory multiple myeloma |
| title_full_unstemmed | The role of carfilzomib in relapsed/refractory multiple myeloma |
| title_short | The role of carfilzomib in relapsed/refractory multiple myeloma |
| title_sort | role of carfilzomib in relapsed refractory multiple myeloma |
| url | https://doi.org/10.1177/20406207211019612 |
| work_keys_str_mv | AT andrewjyee theroleofcarfilzomibinrelapsedrefractorymultiplemyeloma AT andrewjyee roleofcarfilzomibinrelapsedrefractorymultiplemyeloma |